AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition
Says Goodbye To Brazikumab
Executive Summary
The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.